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Vaccination is one of the greatest triumphs of modern medicine, yet we remain largely ignorant of the mech-
anisms by which successful vaccines stimulate protective immunity. Two recent advances are beginning to
illuminate such mechanisms: realization of the pivotal role of the innate immune system in sensing microbes
and stimulating adaptive immunity, and advances in systems biology. Recent studies have used systems
biology approaches to obtain a global picture of the immune responses to vaccination in humans. This
has enabled the identification of early innate signatures that predict the immunogenicity of vaccines, and
identification of potentially novel mechanisms of immune regulation. Here, we review these advances
and critically examine the potential opportunities and challenges posed by systems biology in vaccine
development.‘‘We are drowning in a sea of data and thirsting for knowl-
edge. Most biology today is low input, high throughput, no
output biology.’’ Sydney Brenner
‘‘We must make this the decade of vaccines.’’ Bill Gates
Introduction
In the epic saga of the evolutionary struggle between microbes
and humans, the invention of vaccination is a defining moment,
one that represents the victory of our wits over their genes. Iron-
ically, however, despite the common origins of vaccinology and
immunology in the pioneering work of giants such as Pasteur
and Jenner, the two disciplines have evolved such different
trajectories that immunologists remain largely ignorant about
the mechanisms of action of successful vaccines (empirically
made), and vaccinologists have, until recently, displayed little
interest in the intricacies of immune regulation. Understanding
the immunological mechanisms of vaccination, however, is of
paramount importance in the rational design of future vaccines
against pandemics such as HIV, malaria, and tuberculosis and
against emerging infections. Recent advances in our under-
standing of the innate immune system and the use of systems
biological approaches are beginning to reveal the fundamental
mechanisms by which the innate immune system orchestrates
protective immune responses to vaccination (Pulendran and
Ahmed, 2006; Steinman, 2008). The innate immune system is
capable of sensing viruses, bacteria, parasites, and fungi
through the expression of so-called pattern recognition recep-
tors (PRRs), which are expressed by dendritic cells (DCs) and
other cells of the innate immune system (Reviewed by Coffman,
et al. [2010], this issue of Immunity). Toll-like receptors (TLRs)
represent the most studied family of PRRs (Iwasaki and Medzhi-
tov, 2010; Kawai and Akira, 2010). However, other non-TLR
families of innate receptors, such as C type lectin-like receptors
(Geijtenbeek and Gringhuis, 2009), nucleotide-binding oligomer-
ization domain-like receptors (Ting et al., 2010), and retinoic
acid-inducible gene I (RIG-I)-like receptors (Wilkins and Gale,
2010), also play critical roles in innate sensing of pathogens
and induction of inflammatory responses. Emerging evidence
suggests that the nature of the DC subtype, as well as the
particular PRR triggered, plays a critical role in modulating516 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.the strength, quality, and persistence of adaptive immune
responses (Pulendran and Ahmed, 2006; Steinman, 2008).
Such insights about the molecular basis of immune regulation
have accrued largely through the traditional scientific method
of hypothesis creation, and experimental validation, particularly
through the reductionist approaches of molecular biology.
However, as powerful as such approaches are, they offer
a very limited view of complex biological systems. Thus, there
are estimated to be more than 26,000 genes in our genomes,
and entry of a vaccine or a pathogen into the body perturbs
the expression of a substantial fraction of them. Systems biolog-
ical tools offer us a solution to this problem. In vaccinology,
recent studies have highlighted the use of such approaches in
offering a global picture of the biological response to a vaccine.
Here we highlight these advances and discuss their potential
importance. This review is divided into four parts. In the first
part (Biology of the 21st Century), we provide a broad overview
of systems biology, its goals and challenges, and highlight the
features that distinguish it from reductionistic biology. Next,
(in Systems Biology in Vaccinology) we review recent studies
that have applied systems biological approaches to vaccinology
and suggest key areas where such approaches may impinge
on vaccine development. These include identification of poten-
tially novel correlates of immunity, predicting the efficacy of
vaccines, accelerating the clinical trial platform of vaccines,
and learning new biological insights about immune regulation.
In part three (Low-Input, High-Throughput, No Output Biology),
we critically examine the challenges and potential pitfalls of
systems biological approaches. Finally (in A Framework for
Systems Vaccinology), we conclude by offering a conceptual
framework of how systems approaches can guide vaccine
design and development.
Biology of the 21st Century
Two of the greatest scientific achievements of the 20th century
were the discovery of the structure of DNA and the sequencing
of the human genome. The grand challenge for biology andmedi-
cine at the turn of the 21st century is to understand the biological
complexity that emerges from interactionsbetweenourgenomes
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challenge of biological complexity by the convergence of a new
intellectual framework (a systems rather than a reductionistic
view) and new technologies (for measuring and visualizing the
behavior of genes, molecules, cells, organs, and organisms),
coupled with the innovation of computational and mathematical
tools for dealing with complex data sets. The convergence of
these disparate threads offers us an unprecedented opportunity
to understand the fundamental features of life—from a holistic
rather than solely reductionistic; from a predictive rather than
descriptive; in short, from a systems biological viewpoint.
Systems biology is an interdisciplinary approach that system-
atically describes the complex interactions between all the
parts in a biological system, with a view to elucidating new bio-
logical rules capable of predicting the behavior of the biological
system (Kitano, 2002). Although reductionist molecular biology
works by isolating and characterizing each component of the
system (e.g., a gene, a protein, or a cell type), systems biology
focuses on studying the structure and dynamics of the whole
system (Kitano, 2002). Under different types of perturbation,
data are collected from all the components of a biological
system, analyzed, and integrated in order to generate a mathe-
matical model that describes or predicts the response of the
system to individual perturbations (Ideker et al., 2001). A key
goal of systems biology is to understand the nature of biological
networks, which access, integrate, and communicate informa-
tion from the genome to the environment, and back (Ideker
et al., 2001; Kitano, 2002). These networks represent, in a
sense, the lowest functional units of life processes, such as
development, disease, immunity, and aging. Therefore, under-
standing these life processes requires understanding the nature
and behavior of these networks, both their robustness and
plasticity, in the face of a dynamic environment. What is needed
to delineate these networks is the acquisition of high-
throughput data on the genes, mRNAs, microRNAs, and
proteins that constitute the networks. Systems biology capital-
izes on several so-called ‘‘omic’’ technologies that are used to
define and monitor all the components of the systems. DNA mi-
croarrays and high-throughput sequencing can be applied to
identify global differences on gene expression (transcriptomics),
genomic rearrangements, and genetic polymorphisms (geno-
mics) as well as to provide a high-resolution global map
of protein-DNA interactions (chromatin immunoprecipitation
followed by DNA sequencing or hybridization to the array).
Other enabling technologies include modern mass spectrom-
etry (powering proteomics, lipidomics, and metabolomics),
yeast two-hybrid system (mapping protein interactions), and
genome-wide RNA interference screening (identifying genes
required for a process). In addition, systems biology features
the integration and modeling the huge amount of data gener-
ated by high-throughput techniques. An array of computational
methods has been developed in the context of systems biology,
and data integration and network inference are of special
interest (Bansal et al., 2007; Hyduke and Palsson, 2010). Such
methods can be closely coupled with experimental studies to
generate testable hypotheses and improve the understanding
of molecular mechanisms.
Systems biological approaches have changed prognosis and
therapy response prediction in oncology (Alizadeh et al., 2000;Sørlie et al., 2001) and are beginning to be applied to under-
standing mechanisms of innate and adaptive immunity (Aderem
and Hood, 2001; Germain, 2001; Gilchrist et al., 2006; Haining
et al., 2008; Haining andWherry, 2010; Kaech et al., 2002;Wherry
et al., 2007; Zak and Aderem, 2009), in identifying diagnostic
biomarkers of different infections (Chaussabel et al., 2008; Lee
et al., 2008; Otaegui et al., 2009; Ramilo et al., 2007), and autoim-
munity (Pascual et al., 2010). Systemsbiological approaches also
offer unprecedented opportunities to study immune responses in
humans (Aderem and Hood, 2001; Germain, 2001). However,
only recently have they started to be applied to vaccinology.
There are two broad applications of systems approaches in vac-
cinology: prediction of immunogenicity and efficacy of vaccines
and scientific discovery. These two areas use distinct methodol-
ogies and have different rationales and output, and they are dis-
cussed below.
Systems Biology in Vaccinology
One potential application of systems biology in vaccinology is in
predicting vaccine efficacy.
The identification of molecular signatures (e.g., patterns of
gene expression induced after vaccination), induced rapidly in
the blood after vaccination that correlate with and predict the
later development of protective immune responses, represents
a strategy to prospectively determine vaccine efficacy. In the
field of cancer genomics, predictions of cancer outcome have
been based on gene expression profiles of the cancer cells
themselves (see Box 1). However, in the human immune system,
there is no analogous single tissue fromwhich to sample cells for
dissecting biology and creating predictors. The immune system
spansmultiple lineages, is anatomically distributed, and is highly
interregulated. Sampling all these cellular components and
assaying their gene expression profiles is obviously not feasible.
However, two critical features of the immune response provide
the rationale for applying genomic approaches to study the
response to vaccines. First, cells of the immune system are
easily accessible in peripheral blood samples. Each blood
sample provides a snapshot of many lineages and dozens of
differentiation states within the immune system. Moreover,
because migration and trafficking is a central and ongoing
feature of the immune response, peripheral blood leukocytes
represent recent emigrants of peripheral tissues, including
vaccine sites. Second, cells of the immune system are uniquely
sensitive to perturbation. As discussed below and as we (Querec
et al., 2009) and others (Gaucher et al., 2008) have demon-
strated, individuals who have been vaccinated manifest marked
and characteristic changes in the gene expression profiles of
their peripheral blood leukocytes. Thus, the population of
immune cells in the peripheral blood provides a sensitive bell-
wether of localized or systemic immunologic events.
The first examples of studies using systems biological tools to
understand vaccine-induced immune responses came from two
independent studies that identified early molecular signatures
induced in humans vaccinated with the yellow fever vaccine
YF-17D (Gaucher et al., 2008; Querec et al., 2009). YF-17D is
a live attenuated vaccine, which was generated after serial
passage of a corresponding pathogenic strain (Asibi strain) of
the yellow fever virus (Theiler and Smith, 1937) and is one of
themost successful vaccines ever developed because it confersImmunity 33, October 29, 2010 ª2010 Elsevier Inc. 517
Box 1. Prediction and Classification Based on Gene Expression Signatures
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have received this vaccine and a single immunization results in
a broad spectrum of immune responses (neutralizing antibodies,
cytototoxic T cells, and T helper 1 (Th1) and Th2 cells) and
neutralizing antibody responses that persist for nearly 4
decades. The goal of our study (Querec et al., 2009) was to
use YF-17D as a model to determine the feasibility of applying
systems biological approaches (1) to identify molecular signa-
tures induced early after vaccination, which could predict the
later immunogenicity of the vaccine (i.e., to identify biomarkers
of vaccine efficacy) and (2) to obtain biological insights about
the mechanism of action of YF-17D. Fifteen individuals who
had previously not been vaccinated with YF-17D or infected
with yellow fever (and were thus immunologically naive to the
vaccine or pathogen) were vaccinated, and blood samples
were isolated at baseline and at various time points after vacci-
nation and analyzed with respect to several immunological
parameters. There was a striking variation in the magnitude of
the antigen-specific CD8+ T cell responses, and the neutralizing
antibody titers measured at day 15 or 60, between different indi-
viduals (Querec et al., 2009). We then measured cytokine induc-
tion in the plasma using a multiplex cytokine assay, and the
frequencies and activation status of innate immune cells such
as DC and monocyte subsets at days 1, 3, or 7 after vaccination,
but these measurements did not correlate with the later T cell or
antibody responses. Microarray analyses using the Affymetrix518 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.Human Genome U133 Plus 2.0 array of
total peripheral blood mononuclear cells
(PBMCs) revealed a molecular signature
comprised of genes involved in innate
sensing of viruses and antiviral immunity
inmost of the vaccinees. Thus, in addition
to enhanced expression of endosomal
TLRs, the gene expression of members
of the 20,50-oligoadenylate synthetase
family (e.g., OAS 1,2,3 and L, which are
essential proteins involved in the innate
immune response to viral infection),
DDX58 (RIG-I), and IFIH1 (MDA-5) were
all upregulated (Figure 1). Two key tran-
scription factors that mediate type I inter-
feron responses, IRF7 and STAT1, were
also upregulated. Members of the ISGy-
lation pathway, which preserve essential
proteins from being degraded during the
IFN-induced cellular antiviral state, were
increased, including ISG15, HERC5, and
UBE2L6. Another PRR group where
both positive and negative regulation is
induced by YF-17D is in the complement
cascade. The complement signature of
YF-17D included the upregulation of
genes for C1q and its feedback inhibitor
C1IN and the increased expression
of the gene-encoding C3a receptor 1
with corresponding increase in the C3a
protein in plasma (Figure 1). Thus YF-
17D activates multiple pathogen surveil-
lance mechanisms in several cellularcompartments: extracellular, cell membrane, cytoplasmic, and
vesicular (Figure 1). However, these signatures did not correlate
with the magnitude of the antigen-specific CD8+ T cell or anti-
body responses.
We then used additional bioinformatics approaches to identify
gene signatures that did correlate with themagnitude of antigen-
specific CD8+ T cell responses and antibody titers and that were
capable of predicting the magnitude of these responses in
an independent trial of YF-17D vaccination in humans. We
observed that signatures for CD8+ T cell responses from the first
trial were predictive with up to 90% accuracy in the second trial
and vice versa. Of the genes present in these predictive signa-
tures, EIF2AK4 is known to be a critical player in the integrated
stress response (Wek et al., 2006) and regulates protein
synthesis in response to changes in amino acid levels by phos-
phorylating the elongation initiation factor 2 (eIF2a) (Figure 1).
This results in a global shutdown of translation of constitutively
active proteins by redirection of their mRNAs from polysomes
to discrete cytoplasmic foci known as stress granules (SGs),
where they are transiently stored (Kedersha and Anderson,
2007). Consistent with this, YF-17D induced the phosphorylation
of eIF2a and formation of stress granules (Querec et al., 2009).
Moreover, several other genes involved in the stress response
pathway, like calreriticulin, protein disulfide isomerase, the glu-
cocorticoid receptor, and c-Jun, were observed to correlate
with the CD8+ T cell response (Figure 1). These observations
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Figure 1. Using Systems Biology to Predict the Immunogenicity of the YF-17D Vaccine
Schematic representation of the systems biology approach used to predict the T and B cell responses of YF-17D vaccinees (Querec et al., 2009). Healthy humans
vaccinated with YF-17D are bled at the indicated time points and the innate and adaptive responses studied. Innate signatures obtained with microarrays are
found to correlate with the later adaptive immune responses. The predictive power of such signatures is tested in an independent trial (trial 2).
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stress response in the innate immune system might play a key
role in shaping the CD8+ T cell response to YF-17D. Experiments
to test the hypothesis are currently underway. In the case of anti-
body responses, TNFRSF17 (BCMA), a receptor for the B cell
growth factor BLyS or BAFF (known to play a key role in B cell
differentiation) (Avery et al., 2003), was a key gene in the predic-
tive signatures. Thus, taken together, these studies provide a
global description of the innate and adaptive immune responses
that are induced after YF17D vaccination and stimulate the
generation of testable hypotheses about the biological mecha-
nisms that regulate the magnitude and nature of the immune
response to YF-17D (Figure 1).
The utility of such an approach in predicting the immunoge-
nicity and protective efficacy of other vaccines needs to be
determined. The question of whether the signatures that predict
the T and B cell responses to YF-17D can also predict such
responses to other vaccines remains to be determined. In one
scenario, it could be envisioned that all vaccines that stimulate
antibody responses would induce a common archetypal signa-
ture, capable of predicting the magnitude of the antibody
response to any vaccine. Similarly, there could be an archetypal
signature that predicts the antigen-specific CD8+ T cell
responses to any vaccine. However, B and T cell responses
come in different flavors, and different vaccines induce different
types of B and T cell responses. It seems unlikely, therefore, that
a common archetypal signature would be capable of predicting
all the different types of B or T cell responses induced by different
vaccines. A second scenario is that each vaccine could have
a very unique signature, which was capable of predicting the
particular type of T or B cell responses only to that vaccine.
However, many vaccines induce similar types of immuneresponses (e.g., neutralizing antibodies or polyfunctional CD8+
T cells), so it is reasonable to suggest that vaccines that stimu-
late a similar mechanism of protective immunity will induce
similar molecular signatures. For example, vaccine Y that stimu-
lates long-lived plasma cells that produce high-affinity antibody
may stimulate a particular signature, whereas vaccine Z that
induces polyfunctional CD8+ T cells would stimulate a different
signature (Figure 2). Vaccine X that induced both types of
responses would stimulate a combined signature (Figure 2).
Other vaccines that relied on opsonophagocytic antibodies for
protection may have a different innate signature. Thus, one
would have a cluster of signatures that predict various aspects
of B cell immunogenicity or T cell immunogenicity. Similarly,
there could be a different cluster of signatures that predict
protective immunity that is not mediated by T or B cell-depen-
dent mechanisms, but by other mechanisms mediated perhaps
by NK cells, DCs, or stress response pathways (Figure 2). In this
context, our preliminary data with the influenza vaccines suggest
that TNFRSF17, which was a key predictor of the neutralizing
antibody responses to YF-17D (Querec et al., 2009), is also
a predictor of the hemagglutinin antibody titers to vaccination
with the inactivated influenza vaccine, suggesting that there
are likely to be common predictors of antibody responses to
many vaccines (unpublished data). This probably underlies
common biological mechanisms by which different vaccines
could stimulate antibody responses. The identification of such
predictive signatures will facilitate not only the rapid screening
of vaccines and the development of a vaccine chip, comprising
clusters of a few hundred or fewer genes, each cluster being
capable of predicting a facet of immunogenicity (Figure 2B).
Such a chip would therefore be used to predict the immunoge-
nicity of virtually any vaccine. Indeed, in the field of cancerImmunity 33, October 29, 2010 ª2010 Elsevier Inc. 519
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Figure 2. Construction of a Generic Vaccine Chip
(Top) Systems biology approaches allow the identification of predictive gene signatures of immunogenicity for many vaccines. Vaccines with similar correlates of
protection may or may not share the same genemarkers. The identification of predictive signatures of many vaccines would enable the development of a vaccine
chip. (Bottom) This chip would consist of perhaps a few hundred genes, subsets of which would predict a particular type of innate or adaptive immune response
(e.g., magnitude of effector CD8+ T cell response, frequency of polyfunctional T cells, balance of T helper 1 (Th1), Th2, and Th17 cells, high-affinity antibody titers,
and so on). This would allow the rapid evaluation of vaccinees for the strength, type, duration, and quality of protective immune responses stimulated by the
vaccine. Thus, the vaccine chip is a device that could be used to predict immunogenicity and protective capacity of virtually any vaccine in the future.
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www.agendia.com), a prognostic chip for breast cancer, was
developed by Agendia and approved by the Food and
Drug Administration in the United States. Like the story behind
this breast cancer prognostic chip, the development of the
vaccine chip will probably require the analysis of hundreds of
vaccinees over several clinical trials. However, we have already
seen how host gene expression profiles induced after vaccina-
tion correlate with, and predict, vaccine immunogenicity and
also offer mechanistic insights into immune regulation (Querec
et al., 2009). This additional layer of knowledge, translated into
an array of functional modules on the vaccine chip, gives us extra
power that was not utilized in the earlier, brute-force biomarker
hunting.
This is likely to have an impact on several public health-related
issues in vaccinology. One major issue is that many common
vaccines such as the influenza vaccine (Gardner et al., 2006),
pneumococcal vaccine (Jackson and Janoff, 2008), and zoster
vaccines induce suboptimal immune responses in a substantial
proportion of the elderly, in infants, or in immunocompromised
populations such as HIV-infected or transplant patients. There-
fore, delineation of signatures of immunogenicity would permit
such individuals to be identified prospectively. In addition, this
strategy will help identify nonresponders when vaccinating first
responders during an emerging outbreak or when evaluating
the efficacy or immunogenicity of untested vaccines (Table 1).
Furthermore, the predictive signatures could highlight novel
correlates or protective immunity and enable the formulation of520 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.new hypotheses about the mechanisms underlying vaccine-
induced protective immunity.
Systems biology may also be useful in addressing a major
challenge in vaccine development: to determine the correlates
of protection against a pathogen. The magnitude of the antigen-
specific antibody titers is considered to be the primary correlate
of protection against most pathogens (Plotkin, 2008) (Table 1).
For example, antibodiesmediate protection against blood-borne
viruses such as hepatitis (Jack et al., 1999; Van Damme and Van
Herck, 2007) and yellow fever (Lang et al., 1999; Reinhardt et al.,
1998; Wheelock and Sibley, 1965); bacteria that secrete toxins
that cause diphtheria (Ipsen, 1946) and tetanus (Looney et al.,
1956); viruses that infect via mucosal surfaces such as influenza
(Dowdle et al., 1973; Mostow et al., 1973) and rotaviruses (Jiang
et al., 2008); rabies virus (Nagarajan et al., 2008), which infect
neuronal axons; and pneumococcal and meningococcal
bacteria, which are leading causes of pneumonia and meningitis
(Andreoni et al., 1993; Romero-Steiner et al., 2006). The antigen-
specific antibody responses to such vaccines are measured
through standardized assays such as ELISAs (which measure
binding antibody titers), hemagglutination inhibition, and func-
tional measures of antibody activity such as neutralization and
opsonophagocytosis (Table 1). Typically, such assays yield
a single value, a threshold, above which antibody responses
are considered to be protective.
However, despite thewidespread use of such antibody assays
to measure the efficacy of current vaccines, in the case of many
vaccines humoral immunity may not be the only, or even the
Table 1. Methods to Measure Antibody Correlates of Protection
Vaccine (Pathogen) Test
Correlate of
Protection
Diphtheria
(C.diphtheriae)
Toxin neutralization 0.01–0.1 IU/ml
Hepatitis A ELISA 10 mlU/ml
Hepatitis B ELISA 10 mlU/ml
Hib polysaccharide (Hib) ELISA 1 mg/ml
Hib conjugate (Hib) ELISA 0.15 mg/ml
Influenza HAI 1/40 dilution
Lyme disease ELISA 1100 EIA U/ml
Measles Microneutralization 120 mlU/ml
Pneumococcus
(S. pneumoniae)
ELISA;
opsonophagocytosis
0.2–0.35 mg/ml
(for children);
1/8 dilution
Polio Neutralization 1/4–1/8 dilution
Rabies Neutralization 0.5 IU/ml
Rubella Immunoprecipitation 10–15 mlU/ml
Tetanus Toxin neutralization 0.1 IU/ml
Chickenpox (VZV) FAMA; gpELISA R1/64 dilution;
R5 IU/ml
Historically, correlates of protection have relied on the measurement of
the magnitude of the antigen-specific antibody response stimulated by
vaccination. Such measurements typically include the concentration of
the binding antibody titers (ELISA) or some measure of the activity of
the antibody, such neutralization titers or opsonophagocytic titers.
When a given threshold of such a measurement is achieved or exceeded,
vaccination is assumed to have reached a signature of protective immu-
nization. These tests have become well standardized and relatively
straight forward to perform. The name of the pathogen is included in
parenthesis, where its name is different from the commonly used name
for the vaccine. The following abbreviations are used:C. diphtheria,Cory-
nebacterium diphtheriae; Hib,Haemophilus influenza type B; S. pneumo-
niae, Streptococcus pneumonia; HAI, hemagglutination inhibition; EIA,
enzyme immunoassay; FAMA, fluorescent antibody to membrane anti-
gens; gpELISA, glycoprotein antibody ELISA; VZV, varicella zoster virus.
Adapted from Plotkin (2008).
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may not even correlate with the humoral immune response. Vari-
cella virus vaccination efficacy is usually determined by
measuring antibody titers with serum neutralization or ELISA.
However, persistent varicella-specific T cells have been shown
to be indicators of protection from varicella virus infection and
have been suggested as possible additional or alternative corre-
lates of protection in children and the elderly (Arvin, 2008; Levin
et al., 2008). Furthermore, antibody titers to influenza vaccination
may be unreliable for predicting risk of influenza illness in the
elderly population (McElhaney et al., 2006). On the contrary,
elderly individuals that have strong influenza-specific T cell
responses are less likely to develop flu regardless of postvacci-
nation antibody titers (McElhaney et al., 2006). Although anti-
body titers could not distinguish between elderly subjects that
did or did not develop flu, those subjects with high IFN-g:IL-10
ratios following ex vivo stimulation of PBMCs with live influenza
preparations were more likely to be protected from influenza
illness (McElhaney et al., 2006). In addition, patients with high
frequencies of CMV-specific T cells are less likely to have reac-tivation of CMV when they are placed on immunosuppressive
drugs to prevent transplant rejection (Bunde et al., 2005; Sester
et al., 2001). In fact, many diseases that are a top priority for
vaccine development, such as HIV, TB, andmalaria, are believed
to require strong T cell responses for protection (Hoft, 2008;
Pantaleo and Koup, 2004; Reyes-Sandoval et al., 2009). These
realizations have led to interest in measuring T cells as correlates
of protection.
However, measuring the functional signature of the T cell
response as a correlate of protection is more challenging than
assessing antibody titers. First, T cell populations are phenotyp-
ically and functionally diverse (e.g., CD8+ T cell, CD4+, effector
memory, central memory, Th1, Th2, and Th17 cells, etc.). Vacci-
nation can induce the proliferation and differentiation of antigen-
specific T cells into effector cells that secrete cytokines such as
IFNg, IL-4, IL-17, IL-10, IL-9, or effectormemory cells and central
memory cells, all of which play key roles in mediating short- and/
or long-term protective immunity to the pathogen (Harari et al.,
2004; Sallusto et al., 1999) (Sallusto, et al. [2010], this issue of
Immunity). Recent studies have monitored activated T cells in
humans phenotypically by measuring upregulation of CD38
and HLA-DR or peptide-MHC tetramer-staining cells (Akondy
et al., 2009; Appay et al., 2002; Callan et al., 1998; Morgan
et al., 2008). Differentiation into effector and memory pheno-
types can be assessed by the expression of markers such as
CD45RA, CD62L, CD127, and CCR7 (Akondy et al., 2009; Appay
et al., 2002; Callan et al., 1998; Morgan et al., 2008). However,
the frequencies of differentiated T cell phenotypes may not be
adequate correlates of protection, because these may not
necessarily correlate with their functional activity. The functions
of T cells can be dependent on the cytokines they secrete
(e.g., IFN-g, IL-2, and TNF-a) or production of perforin, as well
as other measures of cell proliferation and cell-mediated cyto-
toxicity. Thus, there are a variety of T cell functional signatures
that can be measured as potential correlates of protection in
lieu of the traditional antibody response. Importantly, the assess-
ment of a single parameter of T cell function (e.g., IFNg secretion)
may not be sufficient as a correlate of protection; however, using
a functional signature comprised of two or more types of
measurementsmay providemore specific and reliable correlates
of protection (Harari et al., 2004). Finally, it may be necessary to
abandon the simple linear functional signature model developed
for antibody titers where a predetermined threshold is used as
a correlate. Instead of using a set threshold of a single variable
to determine vaccine efficacy, so called cocorrelates of protec-
tion may be more appropriate where it is the balance among
multiple variables that indicates efficacy (Qin et al., 2007). For
instance, protection against a pathogen may be achieved
when two conditions are satisfied: (1) the frequency of Th1
CD4+ effector memory cells meets a given threshold and (2)
themagnitudeof the neutralizing antibody titers reaches a certain
threshold. In individuals in whom the thresholds for each of
these conditions are not met, it may be the interaction between
various cocorrelates, and not independent levels of each, that
provides a functional signature of vaccine efficacy. For instance,
in the control of viruses or intracellular pathogens, the lower the
neutralizing antibody titer induced by a vaccine, the higher the
cytotoxic T cell response needs to be to enhance the likelihood
of protection.Immunity 33, October 29, 2010 ª2010 Elsevier Inc. 521
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Figure 3. Integrating Systems Biology Approaches into Clinical Trials
(Top) For vaccines for which correlates or protection are known (Table 1), systems approaches can be used to identify early signatures of protection in a phase 1
trial. The key genes from these signatures can be incorporated into a vaccine chip or ELISA kit, which can then be used to identify nonresponders or suboptimal
responders, particularly in special populations such as immunocompromised patients, the elderly, and infants. (Bottom) For new and emerging vaccines, for
which correlates of protection are unknown, signatures that predict various aspects of immunogenicity (e.g., CD8+ T cell responses or neutralizing antibody
responses) can be assessed in phase I trials. Such signatures can then be incorporated into a vaccine chip or ELISA kit that can then be used in phase II and
III trials to determine their capacity to predict protection. Alternatively, a retrospective nested case-control study could be done in a phase II and III trial to identify
signatures of protection.
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ReviewThe notion that the innate immune response to vaccination
might represent a viable correlate or protection has only recently
been considered. Given the pivotal role of the early innate
response in regulating the magnitude, quality, and duration of
the later adaptive immune responses (Iwasaki and Medzhitov,
2010), specific signatures of innate activation may indicate that
the vaccine induced the appropriate quality and sufficient
strength of activation to induce protective acquired immunity.
As discussed above, it has been shownwith yellow fever vaccine
17D that molecular signatures in the blood 3 to 7 days after
vaccination, corresponding with vaccine viremia and activation
of the innate immune pathways, may be used to predict the
peak frequency of activated virus-specific T cells and long-
term neutralizing antibody titers (Querec et al., 2009).
How can systems approaches be integrated into the clinical
trial framework to identify correlates of protective immunity? At
the outset, it is important to clarify a frequent source of confusion
that arises regarding correlates of immunogenicity versus corre-
lates of protection. The ultimate goal is of course to determine
vaccine-induced signatures a few hours or days after vaccina-
tion that can predict whether a given individual will develop
long-term protective immunity against the pathogen. The most
logical way of addressing this goal is to perform a clinical trial
in which vaccinated humans can be challenged with the path-
ogen and then to identify signatures that would discriminate
between those vaccinees who succumbed to the infection522 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.versus those who were protected. With very rare exceptions,
as in the case of malaria vaccine trials (Vahey et al., 2010),
such an approach is clearly untenable ethically and thus alterna-
tive approaches must be considered. One alternative approach
is to use animal challenge models in which vaccines can be eval-
uated. Such models, such as the nonhuman primate model for
HIV or the ferret model for influenza have greatly accelerated
vaccine discovery and offeredmuch insight into themechanisms
of protection (Sui et al., 2010). However, in some cases, opinions
vary regarding the relative merits of a given model and how to
translate results obtained from such a model into the clinic
(Morgan et al., 2008). Therefore, an alternative or even comple-
mentary approach is to identify signatures of immunogenicity
to the vaccine in humans. This approach relies on the axiom
that immune protection against a pathogen is mediated by one
or more components of the immune response, which can
broadly be divided into the adaptive (antigen-specific B and
T cells) and the innate responses. Therefore, if there was a priori
knowledge of precisely which component(s) of the immune
response (e.g., a combination of persistent neutralizing antibody
responses and memory CD8+ T cells that migrate to mucosal
tissues), then it becomes relatively straightforward to conduct
a phase 0 or 1 clinical trial (similar to the yellow fever vaccine
trials) in which early predictive signatures of such responses
can be identified (Figure 3). Such signatures can then be applied
in the clinic to identify vaccinees who will respond suboptimally
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responses are necessary for protection? In many cases, we
can be guided bymore than a century of immunological wisdom.
For example, few immunologists would deny that the induction
of persistent neutralizing antibody responses (Table 1) and cyto-
toxic T cells are beneficial to fight most viral infections. In such
cases, early signatures that various aspects of T or B cell immu-
nogenicity can be assessed in a high-throughput manner, using
a small number of genes (Vaccine Chip) or an ELISA kit that
measured protein expression (Figure 3).
But what happens in situations in which the types of immune
responses required for protection are not readily apparent or
where the full range of responses required for optimally effective
protection may be unknown? For example, in HIV infections,
although neutralizing antibodies and cytotoxic T cells are
thought to be important (Letvin, 2007), there is much interest in
ascertainingwhether there are additional mechanisms thatmight
confer protection. Here, it is interesting to consider how systems
approaches may be integrated into phase II and III clinical trials,
with a view to identifying new correlates of protection. Two
approaches to integrating systems approaches into phase II
and III trials are shown in Figure 3. Such trials typically involve
thousands of participants, and performing high-throughput anal-
yses on all would be prohibitively expensive. In one approach,
signatures of various aspects of T and B cell immunogenicity
can be established in a smaller phase I trial, and these signatures
can be incorporated into a relatively cheap and high-throughput
assay that can be used to predict immunogenicity in phase II
and III trials (Figure 3). The assumption here is that some aspect
of the T or B cell response will be protective. In a different
approach, blood samples could be collected at a few strategic
time points (e.g., days 0 and 7 after vaccination), put straight
into RNA lysis buffer, and stored for future use. Once the trial
was completed, a retrospective nested case-control study could
be performed using the stored samples in which a detailed anal-
yses of innate and adaptive responses could be performed in,
say, 50 vaccinees who acquired the disease and 50 vaccinees
who did not. The goal would be to identify signatures induced
early on that would discriminate between those who were pro-
tected by the vaccine versus those who were not. A caveat
with this approach is that one would not know whether those
vaccinees who didn’t acquire the disease were actually pro-
tected by the vaccine or simply never encountered the pathogen.
However, in many endemic areas of infection (e.g., in a rural area
where cholera is endemic and access to clean drinking water is
absent), it may be assumed that exposure to infection is high.
A potential benefit of using functional signatures of innate
immunity as correlates of protection is that they occur quite early
after vaccination compared to the development of memory
T cells and antibody responses, which can take weeks, months,
or years. Being able to determine vaccine efficacy in a short time
is useful for many reasons. The current clinical trial format is very
lengthy and costly and usually offers no insights intowhy apartic-
ular vaccine failed. As such, clinical trials represent a major rate-
limiting step in vaccine development. Having a shorter study
period increases the probability of retaining all the subjects for
the duration of the study, increasing the proportion of subjects
that are tracked from vaccination through the final time point.
In addition, measuring functional signature of vaccine-inducedinnate immunity makes high-throughput screening of vaccine
candidates more feasible. The short duration of time required
to measure innate immune activation relative to the endpoints
of acquired immunity means: (1) shorter duration to analyze
each batch of vaccine candidates, (2) potentially fewer resources
and costs devoted to the early stage analysis of each vaccine
candidate, (3) quicker refinement of vaccine formulations and
delivery methods, and (4) identification of why a particular
vaccine failed (Figure 3).
Apart from lack of inducing sufficient protection, another
common reason for vaccines to fail is severe side effects. These
side effects are often associated with overactivation of certain
components of the innate immune system (Gupta et al., 1993;
Pulendran et al., 2008). Thus functional signatures of innate
immunity may be used to screen adjuvants or as cocorrelates
of protection along with parameters of acquired immunity for
complete vaccines (antigen + adjuvant). Functional signatures
may not only help in the design of protective vaccines but may
also help to limit the deleterious side effects.
Finally, systems approaches could also yield biological
insights about how vaccines work.
One area that could benefit from systems approaches is delin-
eation of the mechanisms by which adjuvants work. Although
the empiric, live attenuated vaccines contain stimuli that activate
the innate immune system and, in effect, act as their own adju-
vants, recombinant vaccines such as the Hepatitis B vaccine
need to be administered with exogenous adjuvants. In the nearly
250 years since the introduction of vaccination, although a great
variety of adjuvants have been proposed, until very recently only
alum, described by Glenny in 1926, was globally licensed for
human use (De Gregorio et al., 2008; Lindblad, 2004). However,
alum is a Th2 cell-inducing adjuvant, and does not induce
strong Th1 and CTL responses. Thus, there is an urgent need
to develop alternative and safe adjuvants that induce different
types of immune response that might be optimally effective
against different pathogens. Despite its widespread utility, until
very recently its mechanism of action has been shrouded in
mystery. It has been suggested that alum works by serving as a
depot of antigen in the body. It has also been suggested that
alum could cause necrosis in the inoculated tissue, which indi-
rectly activates DCs through danger signals in the form of host
inflammatory mediators (De Gregorio et al., 2008; Mbow
et al., 2010). The details of this mechanism are only now being
revealed. Recently it was demonstrated that alum signals via
the Nalp3 inflammasome (Eisenbarth et al., 2008; Kool et al.,
2008; Li et al., 2008). Thus, DCs or macrophages stimulated
in vitro with alum plus LPS induced IL-1b and IL-18 in a cas-
pase-1- and Nalp3-dependent manner (Eisenbarth et al., 2008;
Kool et al., 2008; Li et al., 2008; McKee et al., 2009). Despite
the convincing in vitro studies, the question of whether Nalp3 is
required for the adjuvanticity of alum remains controversial,
with some studies demonstrating abrogation of antibody
responses in Nalp3-deficient (Nlrp3/) mice (Eisenbarth et al.,
2008; Li et al., 2008) andother studies showing partial or no effect
(Kool et al., 2008; McKee et al., 2009). Thus, the mechanisms by
which alum induces Th2 responses are poorly understood, and
a systems biological approach (e.g., microarray analyses of
signatures in response to an alum-adjuvanted versus unadju-
vanted vaccine) is likely to be useful in providing new insightsImmunity 33, October 29, 2010 ª2010 Elsevier Inc. 523
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performed an elegant study in mice to assess the molecular and
cellular signatures of vaccine adjuvants, including the squalene-
based oil-in-water emulsion MF59 (Mosca et al., 2008), which
was licensed for human use a decade ago. The molecular mech-
anism of action and the target cells of alum and MF59 are still
unknown. By combining microarray and immunofluorescence
analysis, Mosca et al. monitored the effects of the adjuvants
MF59, CpG, and alum in the mouse muscle. MF59 induced the
expression of 891 genes; in contrast, CpG and alum regulated
387 and 312 genes, respectively. Interestingly, there was a core
set of 168 genes that were modulated by all adjuvants. Although
all adjuvants promoted the recruitment of antigen-presenting
cells, MF59 triggered a more rapid influx of CD11b+ blood cells
compared with other adjuvants. Furthermore, MF59 was the
most potent inducer of genes encoding cytokines, cytokine
receptors, and adhesion molecules involved in leukocyte migra-
tion. Intriguingly, two genes identified by microarrays, JunB and
Ptx3, suggested skeletal muscle as a direct target of MF59.
Taken together, the authors’ interpretation of the data suggests
that oil-in-water emulsions are efficient human vaccine adjuvants
because they induce an early and strong immunocompetent
environment at the injection site by targeting muscle cells. In
addition, we have recently applied this approach to identifying
a novel mechanism by which adjuvants that induce Th2
responses (e.g., cysteine proteases) program DCs to stimulate
Th2 responses (Tang et al., 2010). This involves the induction of
reactive oxygen species (ROS) in DCs, which is critical for the
induction of Th2 responses (Tang et al., 2010).
These studies demonstrate the utility of systems approaches
in understanding the mechanism of action of adjuvants, and in
identifying mechanisms that contribute to their toxicity. In addi-
tion, emerging work in innate immunity is revealing the mode
of action ofmany adjuvants. Under the brand nameAS04,mono-
phosphoryl lipid A (MPL), an LPS derivative and a TLR4 ligand, is
used in combination with alum in Cervarix, GlaxoSmithKline’s
recently approved human papillomavirus vaccine (Hennessy
et al., 2010). With the growing number of adjuvants at our
disposal to mimic natural infections, we need a frame of refer-
ence as to how to use them for maximum efficacy. Turning to
the functional signatures of innate immunity induced by some
of our most successful vaccines is beginning to shed light
on this area. For example, YF-17D activates multiple TLRs,
including TLR 2, 7, 8, and 9, as well as non-TLR PRRs such as
RIG-I and MDA-5 (Querec et al., 2006, 2009), which results in
the activation of plasmacytoid DCs and myeloid DCs. Similar
approaches are being applied to understand innate responses
to other vectors such as the attenuated pox vectors modified
vaccinia virus Ankara and New York vaccinia (Guerra et al.,
2007) and baculovirus-expressed HIV virus-like particles (Buo-
naguro et al., 2008).
Systems approaches can also shed light on the mechanisms
by which vaccines induce a given type of response. As dis-
cussed above, one of the key genes in the predictive signature
of YF-17D, EIF2AK4, is known to be a critical player in the inte-
grated stress response (Kedersha and Anderson, 2007) and
regulates protein synthesis in response to changes in amino
acid amounts by phosphorylating the elongation initiation factor
2 (eIF2a) (Figure 1). Our recent data demonstrate that immuniza-524 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.tion of mice deficient in EIF2AK4with YF-17D results in substan-
tially diminished CD8+T cell responses (unpublished data). The
precise mechanism of this is under investigation, but this result
demonstrates that the integrated stress response plays a key
role in regulating adaptive immunity to a viral vaccine.
Finally, it is important to remember that the complex behavior
of biological systems cannot be understood by studying parts in
isolation (Germain, 2001; Ideker et al., 2001; Kitano, 2002; Weng
et al., 1999). Therefore, vaccinologists need to move beyond
merely understanding each of the parts of the immune system
in isolation to instead understand how the different parts of the
immune system interact among themselves. Indeed, a unified
model of the cellular and molecular mechanisms of vaccine-
induced protective immunity is likely to result from studying
different hierarchies of organization with the immune system.
In such a hierarchy, the cell can be considered to be the ground
level, and zooming into the cell to examine innate receptors
and signaling networks offers greater conceptual resolution. In
contrast, zooming out from the cell, allows more global views
of multicellular cooperation (e.g., between DC subsets) and the
influence of tissue microenvironments (e.g., intestine versus
lung) (Pulendran et al., 2010). In addition, the immune system,
as with all biological systems, has redundancies, feedback and
feed-forward regulation, and synergism, which all impact how
the instruction of the vaccine is processed (Kitano, 2002). For
example, combinatorial triggering of specific combinations of
TLRs results in a synergistic production of proinflammatory cyto-
kines via a mechanism dependent on TRIF and MyD88 signaling
(Napolitani et al., 2005). Consistent with this, vaccination with
nanoparticles containing particular combinations of TLR ligands
plus antigens induced a synergistic enhancement in the magni-
tude and persistence of antigen-specific memory B cells and
long-lived plasma cells (unpublished data).
Low-Input, High-Throughput, No Output Biology?
Despite the promise of systems approaches in vaccinology,
we may do well to heed the advice of Dr. Sydney Brenner:
‘‘The idea that we’ll dissect [cellular] complexity by making lots
of measurements is bound to fail.. Everyone’s hoping for
a magic computer program—experimental data, pharmacoge-
nomics data, the whole lot—and it will come out with the answer.
That’s a vague hope. Because I have to tell you, computers are
incredibly stupid! It’s better to combine human intelligence with
artificial stupidity than the other way around’’ (Davies, 2008), and
‘‘Actually, the orgy of fact extraction in which everybody is
currently engaged has, like most consumer economies, accu-
mulated a vast debt. This is a debt of theory, and some of us
are soon going to have an exciting time paying it back—with
interest, I hope’’ (Brenner, 1997). The accumulation of a sea of
data is but a small stepping stone toward real understanding
of biological systems. It is imperative to get beyond colorful
heat maps and network maps to an understanding of the func-
tional significance of the molecular signatures of vaccination.
This is a daunting challenge because of several intrinsic prob-
lems in this approach. These are discussed below.
Conceptual Problems
A major conceptual pitfall lies with the premise that changes in
the expression of genes in response to vaccination may neces-
sarily be functionally relevant for generating the immune
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genes that are modulated in response are of no consequence
to the biological response to that stimulus because evolution
has not had a reason for silencing those genes. Indeed, it is
well recognized that gene coexpression only corresponds to
causality in very limited cases (Bansal et al., 2007; Schadt
et al., 2005). The challenge is to identify true causal relationships
among the cooccurring events. One solution is to borrow knowl-
edge from predefined gene modules or pathways. If multiple
geneswithin amodule are coordinately regulated by the vaccine,
then the likelihood that this module is functionally relevant
becomes much higher. Another approach is to combine multiple
data types. As Chen et al. (Chen et al., 2008) demonstrated,
a macrophage-enriched metabolic network, derived by inte-
grating genotyping data and expression data, was causal of
obesity traits, whereas each data type alone could not deliver
the predictive power. We should be reminded that the current
measurements are still a thin slice of immense biological
complexity; microarray data, even with a large sample size,
may fail to reach any statistical significance (Dixon et al.,
2007). The general question is: how much data, what data, at
what resolution, at what scale, are needed to explain the immu-
nological phenotypes? This may only be addressed in each indi-
vidual case through trials and errors. Finally, the results of the
analysis have to be validated by functional data via proven tech-
niques, say, gene perturbation or deficient mice. As the study
design is closely coupled with computational analysis and
modeling, systems biology is best done in an environment where
biologists and computational scientists interact closely.
A second conceptual problem is the premise that we can
deduce mechanistic insights about how the vaccine-induced
immune responses by looking at changes in the expression of
genes only in cells isolated from the blood. This is a significant
problem because immune response to local vaccinations will be
initiated in the draining lymph nodes. However, with many
vaccines, suchas live viral or bacterial vectors, there is a transient,
systemic replicationof the vector and, subsequently, a direct acti-
vation of blood leukcocytes by the it. This is likely to produce the
profile of gene expression changes observed in the draining
lymph nodes, which serves as a surrogate for immunogenicity.
Even in the case of nonreplicating vaccines such as the inacti-
vated influenzavaccine, our result results demonstrate that signa-
tures of immunogenicity can be ascertained in the blood (unpub-
lished data). An additional problem is that, for many vaccines that
induce mucosal immunity, gene expression signatures in the
blood many not predict the strength, quality, and duration of
mucosal immunity. Sampling mucosal tissues in human vacci-
nees is wrought with challenges. Clearly further studies are
necessary to ascertain the extent to which immunogenicity of
mucosal vaccines can be ascertained from the blood.
Technical Problems
One of the key technical issues is that gene expression signa-
tures are prone to artifacts. Since the early studies of cancer
expression microarrays, questions have been raised about how
robust the gene signatures are (Ein-Dor et al., 2006). Recently,
emphasis has been placed on pathway and network analyses
because they incorporate prior knowledge into data analysis
and are less prone to spurious errors than analyses of individual
genes (Chuang et al., 2007; Dinu et al., 2009). This is particularlyrelevant to immunological studies where signals are often diluted
by cell heterogeneity (Haining and Wherry, 2010). In addition,
signatures must be validated with additional techniques and
independent samples.
Second, when profiling PBMCs, one is looking at signatures
from a mixed bag of cells. Therefore, the extent to which the
changes in gene expression reflect alterations in the cellular
composition of the blood versus de novo induction of gene
expression remains uncertain. One solution to this problem is
to FACS sort subpopulations of cells and then to evaluate
expression profiles in individual cell types. However, this
approach is rather laborious and expensive. An alternative
approach is to devise computational strategies for assessing
cell type-specific gene expression profiles. Recently, Shen-Orr
et al. (Shen-Orr et al., 2010) have devised such an approach
using microarray data and relative cell type frequencies. First
they validated their approach using predesigned mixtures of
cells, and then they applied it to whole-blood gene expression
datasets from stable posttransplant kidney transplant recipients
and those experiencing acute rejection.
A third challenge lies in the enormous genetic and environ-
mental heterogeneity in human populations and the impact
that such heterogeneity may have on vaccine-induced immunity.
Therefore, future studies should strive to conduct such research
in populations that are uniform with respect to age, gender,
ethnicity, and immune status. Furthermore, studies that aim to
compare vaccine-induced immunity between different popula-
tions (e.g., frail elderly versus healthy adults) are likely to yield
many insights into mechanisms that contribute to impaired
immunity in given populations.
Fourth, a major challenge concerns data management and
integration of the enormous volume of data generated. The
timely sharing of these data is important to the research commu-
nity. A dedicated database service for vaccine-related data, akin
to WormBase (Schwarz et al., 2006) and TB database (Reddy
et al., 2009), should be created as soon as possible. Public data-
bases for immunology, including InnateDB (Lynn et al., 2008)
and Immgen.org (Heng and Painter, 2008), have been well
covered by recent reviews (Gardy et al., 2009; Tong and Ren,
2009). In-house databases often become a necessity for high-
throughput projects. Integration of multiple data types is usually
driven by the specific modeling approach, for instance by naive
Bayesian methods (Huttenhower et al., 2009) or by custom
algorithms, or combined by biomolecular concepts (Joyce and
Palsson, 2006). For example, transcription factor binding data
and gene expression are combined under frameworks of tran-
scriptional regulation; metabolites and enzyme expression are
combined in metabolic networks. Broader and more definitive
immune parameters are desired (Fauci et al., 2008).
Cultural Problems
Finally, the successful application of systems approaches to
vaccinology requires a close transdisciplinary collaboration
between biologists and computational scientists. It is critical
that such individuals engage in active dialog on a daily basis
to combine rigorous bioinformatics analyses of the data with
biological insights and intuition. Such intimate collaborations
could even take place within a single laboratory where, for
example, post-docs trained in bioinformatics and biology
interact closely.Immunity 33, October 29, 2010 ª2010 Elsevier Inc. 525
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Figure 4. A Framework for Systems Vaccinology
Systems biology approaches applied to clinical trials can
lead to the generation of new hypotheses that can be
tested and ultimately lead to developing better vaccines.
For example, immune responses to vaccination in clinical
trials can be profiled in exquisite depth with technologies
such as microarrays, deep sequencing, and proteomics.
The high-throughput data generated can be mined using
bioinformatics tools and used to create hypotheses about
the biological mechanisms underlying vaccine-induced
immunity. Such hypotheses can then be testedwith animal
models or in vitro human systems. The insights gained
from experimentation can then guide the design and
development of new vaccines. Such a framework seeks
to bridge the so-called gaps between clinical trials and
discovery-based science, between human immunology
and mouse immunology, and between translational and
basic science and offers a seamless continuum of scien-
tific discovery and vaccine invention.
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At the World Economic Forum’s annual meeting in Davos this
year, Bill Gates pledged $10 billion for vaccines over the next
decade and said that he hoped that the coming 10 years
would be the decade of the vaccine. His words symbolize
the uniquemoment we face today in our millennial war with path-
ogens. For the first time, we have begun to understand the
mechanisms by which highly successful vaccines mediate
protective immunity and to begin to harness such insights
in designing new vaccines against global pandemics. Systems
biology promises to offer a new paradigm in vaccinology.
Recently, the National Institute of Allergy and Infectious Dis-
eases (NIAID) initiated a new nationwide initiative to establish
a consortium of human immune profiling research centers
(National Institute of Allergy and Infectious Diseases, 2010).
The purpose of these centers—which together will receive
funding up to $100 million over 5 years—is to characterize the
human immune system under normal conditions and to under-
stand how it changes following infection or vaccination to
specific viruses and bacteria. Researchers will use the tools of
systems biology to follow the global architecture of the immune
response to vaccination or infections in humans and integrate
information about an individual’s genes, proteins, and metabolic
components that are perturbed by vaccination or infection.
Such studies will be performed in diverse populations with
respect to age (including the elderly and children), immune
status (including people with autoimmune diseases such as
lupus and transplant patients), gender, and ethnicity. In addition,
the initiative will provide support for centralized infrastructure to
collect, characterize, and store the human samples; for bioinfor-
matic capacity to analyze the large and complex data sets that
will be generated; and for the discovery and development of
new immune response-monitoring tools and sample-sparing526 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.assays. The results of this initiative are likely
to have a major impact on vaccinology and
generate an unprecedented volume of data on
immune responses in humans. However, we
must remember Dr. Brenner’s admonishment
and strive to transcend data and discover
knowledge and ultimately understanding. The
generation of high-throughput data representsbut a stepping stone toward understanding. An essential aspect
of this is to integrate mechanistic studies involving models, both
animal and human, (e.g., knockout mice, transgenic mice, siRNA
knock down of genes in humans cells in vitro) that can elegantly
validate the functions of genes and proteins picked up in the
human immune-profiling studies (Figure 4). Therefore, data
generated in clinical trials can be mined using bioinformatics
tools and used to generate biological hypotheses, which can
then be tested with animal models or in vitro systems. The
insights gained from experimentation will then guide the design
and development of new vaccines (Figure 4). Such a framework
seeks to bridge the so-called gaps between clinical trials and
discovery-based science, between human immunology and
mouse immunology, and between translational and basic
science and offers a seamless continuum of scientific discovery
and vaccine invention. That would be emblematic of 21st century
vaccinology!
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